These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 29897513)

  • 1. Evaluation of adhesion molecules and immune parameters in HIV-infected patients treated with an atazanavir/ritonavir- compared with a lopinavir/ritonavir-based regimen.
    Squillace N; Trabattoni D; Muscatello A; Sabbatini F; Maloberti A; Giannattasio C; Masetti M; Fenizia C; Soria A; Clerici M; Gori A; Bandera A
    J Antimicrob Chemother; 2018 Aug; 73(8):2162-2170. PubMed ID: 29897513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) use correlates with elevate markers of atherosclerosis in HIV-infected subjects in Addis Ababa, Ethiopia.
    Gleason RL; Caulk AW; Seifu D; Parker I; Vidakovic B; Getenet H; Assefa G; Amogne W
    PLoS One; 2015; 10(4):e0117125. PubMed ID: 25915208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir.
    Laker EAO; Nabaggala MS; Kaimal A; Nalwanga D; Castelnuovo B; Musubire A; Kiragga A; Lamorde M; Ratanshi RP
    BMC Infect Dis; 2019 Mar; 19(1):280. PubMed ID: 30909871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Reconstitution but Persistent Activation After 48 Weeks of Antiretroviral Therapy in Youth With Pre-Therapy CD4 >350 in ATN 061.
    Rudy BJ; Kapogiannis BG; Worrell C; Squires K; Bethel J; Li S; Wilson CM; Agwu A; Emmanuel P; Price G; Hudey S; Goodenow MM; Sleasman JW;
    J Acquir Immune Defic Syndr; 2015 May; 69(1):52-60. PubMed ID: 25942459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defining a Cutoff for Atazanavir in Hair Samples Associated With Virological Failure Among Adolescents Failing Second-Line Antiretroviral Treatment.
    Chawana TD; Gandhi M; Nathoo K; Ngara B; Louie A; Horng H; Katzenstein D; Metcalfe J; Nhachi CFB;
    J Acquir Immune Defic Syndr; 2017 Sep; 76(1):55-59. PubMed ID: 28520618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral neuropathy in HIV patients in sub-Saharan Africa failing first-line therapy and the response to second-line ART in the EARNEST trial.
    Arenas-Pinto A; Thompson J; Musoro G; Musana H; Lugemwa A; Kambugu A; Mweemba A; Atwongyeire D; Thomason MJ; Walker AS; Paton NI;
    J Neurovirol; 2016 Feb; 22(1):104-13. PubMed ID: 26323809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV antiretroviral drugs, dolutegravir, maraviroc and ritonavir-boosted atazanavir use different pathways to affect inflammation, senescence and insulin sensitivity in human coronary endothelial cells.
    Auclair M; Guénantin AC; Fellahi S; Garcia M; Capeau J
    PLoS One; 2020; 15(1):e0226924. PubMed ID: 31971958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-classical monocytes predict progression of carotid artery bifurcation intima-media thickness in HIV-infected individuals on stable antiretroviral therapy.
    Chow DC; Kagihara JM; Zhang G; Souza SA; Hodis HN; Li Y; Mitchell BI; Nakamoto BK; Kallianpur KJ; Keating SM; Norris PJ; Kohorn LB; Ndhlovu LC; Shikuma CM
    HIV Clin Trials; 2016 May; 17(3):114-22. PubMed ID: 27125366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current evidence for the risk of PR prolongation, QRS widening, QT prolongation, from lopinavir, ritonavir, atazanavir, and saquinavir: A systematic review.
    Ridjab DA; Ivan I; Budiman F; Juliawati DJ
    Medicine (Baltimore); 2021 Aug; 100(31):e26787. PubMed ID: 34397829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic inflammation in pregnant women with HIV: relationship with HIV treatment regimen and preterm delivery.
    Shivakoti R; Giganti MJ; Lederman MM; Ketchum R; Brummel S; Moisi D; Dadabhai S; Moodley D; Violari A; Chinula L; Owor M; Gupta A; Currier JS; Taha TE; Fowler MG;
    AIDS; 2024 Jul; 38(8):1111-1119. PubMed ID: 38411599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of changes in cognitive function after the initiation of antiretroviral therapy.
    Mora-Peris B; Stevens E; Ferretti F; Underwood J; Taylor S; Winston A
    AIDS Res Ther; 2016; 13():20. PubMed ID: 27081393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poorer Muscle Quality and Quantity With ART Initiation Is Associated With Greater Inflammation and Immune Activation.
    Kousari A; Moser C; Olefsky M; Brown TT; Currier JS; McComsey GA; Scherzinger A; Stein JH; Lake JE; Erlandson KM
    J Acquir Immune Defic Syndr; 2021 Dec; 88(4):399-405. PubMed ID: 34326283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal Changes in Subclinical Vascular Disease in Ugandan Youth With Human Immunodeficiency Virus.
    Dirajlal-Fargo S; Zhao C; Labbato D; Sattar A; Karungi C; Longenecker CT; Nazzinda R; Funderburg N; Kityo C; Musiime V; McComsey GA
    Clin Infect Dis; 2023 Feb; 76(3):e599-e606. PubMed ID: 36004575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s.
    Venuto CS; Lim J; Messing S; Hunt PW; McComsey GA; Morse GD
    Antivir Ther; 2018; 23(4):345-351. PubMed ID: 29171837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nine-year follow-up of HIV-infected Romanian children and adolescents receiving lopinavir/ritonavir-containing highly active antiretroviral therapy.
    Wanless RS; Rugină S; Ruţă SM; Dumitru IM; Cernat RC; Schwarzwald HL; Calles NR; Schutze GE; Schweitzer AM; Draper HR; Kline MW
    Germs; 2013 Sep; 3(3):90-5. PubMed ID: 24432292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PLWH treated with modern ART and high CD4 T cell counts: no evidence of HIV-associated vasculopathy measured by extra- and intracranial ultrasound.
    Fousse M; Heit M; Fassbender K; Kaddu-Mulindwa D
    Acta Neurol Belg; 2024 Feb; 124(1):363-365. PubMed ID: 37490199
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study.
    Lê MP; Chaix ML; Chevret S; Bertrand J; Raffi F; Gallien S; El Abbassi EMB; Katlama C; Delobel P; Yazdanpanah Y; Saillard J; Molina JM; Peytavin G;
    J Antimicrob Chemother; 2018 Aug; 73(8):2120-2128. PubMed ID: 29905808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stable HIV-1 reservoirs on dolutegravir maintenance monotherapy: the MONODO study.
    Sculier D; Doco-Lecompte T; Yerly S; Metzner KJ; Decosterd LA; Calmy A
    HIV Med; 2018 Jun; 19(8):572-7. PubMed ID: 29932298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronic acid is superior to tenofovir disoproxil fumarate-switching for low bone mineral density in adults with HIV.
    Hoy JF; Richardson R; Ebeling PR; Rojas J; Pocock N; Kerr SJ; Martinez E; Carr A;
    AIDS; 2018 Sep; 32(14):1967-1975. PubMed ID: 29927785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology of human immunodeficiency virus (HIV) drug resistance in HIV patients with virologic failure of first-line therapy in the country of Georgia.
    Karkashadze E; Dvali N; Bolokadze N; Sharvadze L; Gabunia P; Karchava M; Tchelidze T; Tsertsvadze T; DeHovitz J; Del Rio C; Chkhartishvili N
    J Med Virol; 2019 Feb; 91(2):235-240. PubMed ID: 29905958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.